Quest Diagnostics Incorporated (DGX) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Stable margins ⢠Strong cash flow ⢠Moderate leverage DGX looks like a steady cash-generating business with solid profitability and dividend coverage, but moderate leverage, limited cash, and an intangible-heavy balance sheet mean the stock is more fairly valued than cheap.
Price Behavior
Key Price Behavior Insights: ⢠Range support ⢠Resistance rejection ⢠Short-term pullback Support Level: $191â$196 Resistance Level: $200â$205 DGX has been flat over the last month but has weakened recently, with repeated failures near $200â$205 and support holding around $191â$196, making the near-term setup more cautious than constructive.
Sentiment & News
Key News Insights: ⢠Earnings Beat ⢠Guidance Raise ⢠Oncology Adoption DGX showed strong late-April momentum as Quest Diagnostics beat Q1 expectations, raised full-year guidance, and added a key oncology win with its Haystack MRD test.
AI Summary
DGX has shifted from a steady defensive name to a credible earnings-acceleration story, with raised guidance, strong cash flow, and selective growth in oncology/MRD and AI tools, but at ~23x earnings and with leverage/intangibles still limiting downside protection, the stock needs sustained execution to justify further upside.
Description
Quest Diagnostics is a provider of diagnostic testing and related information services in the U.S. and internationally, offering a spectrum of laboratory testing from routine to advanced clinical and anatomic pathology under multiple brands. Its customers include patients, clinicians, hospitals, health plans, employers and life insurers, and it delivers services through laboratories, patient service centers, physician-office phlebotomists, mobile clinicians and call centers. The company also supplies life-insurance risk assessment services and health care IT solutions and is headquartered in Secaucus, New Jersey, where it was founded in 1967.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 27 | Mar 6 | DGX | Quest Diagnostics Incorporated | Quest Diagnostics rallied ~28.5% over 21 days on a Q4/FY2025 beat, above-Street FY2026 guidance, a $1B buyback expansion and 7.5% dividend hike; strong FCF and advanced diagnostics launches (Haystack MRD, CoLab expansion) support near-term continuation from pullbacks toward the 190â205 support band. | Closed | -6.0% |